Suchen
Cellectis SA
CLLSZur Watchlist hinzufügen
3.300USD
+0.360+12.24%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
238.67MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Cellectis SA Unternehmen
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Cellectis SA Informationen
BörsenkürzelCLLS
Name des UnternehmensCellectis SA
IPO-datumFeb 06, 2007
CEOSourdive (David J.D)
Anzahl der mitarbeiter224
WertpapierartDepository Receipt
GeschäftsjahresendeFeb 06
Addresse8, rue de la Croix Jarry
StadtPARIS
BörseNASDAQ OMX - NASDAQ BASIC
LandFrance
Postleitzahl75013
Telefon33181691600
Websitehttps://www.cellectis.com/
BörsenkürzelCLLS
IPO-datumFeb 06, 2007
CEOSourdive (David J.D)
Führungskräfte von Cellectis SA
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Dr. David Sourdive, Ph.D.
Dr. David Sourdive, Ph.D.
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Pierre Bastid
Mr. Pierre Bastid
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Laurent Arthaud
Mr. Laurent Arthaud
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Rainer J. Boehm, M.D.
Dr. Rainer J. Boehm, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stephan Reynier
Mr. Stephan Reynier
Chief Regulatory and Pharmaceutical Compliance Officer
Chief Regulatory and Pharmaceutical Compliance Officer
--
--
Ms. Marie-Bleuenn Terrier
Ms. Marie-Bleuenn Terrier
General Counsel
General Counsel
--
--
Mr. Arthur Stril
Mr. Arthur Stril
Chief Financial Officer and Chief Business Officer
Chief Financial Officer and Chief Business Officer
--
--
Dr. Steven (Steve) Doares, Ph.D.
Dr. Steven (Steve) Doares, Ph.D.
Senior Vice President - US Manufacturing
Senior Vice President - US Manufacturing
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Dr. David Sourdive, Ph.D.
Dr. David Sourdive, Ph.D.
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Pierre Bastid
Mr. Pierre Bastid
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Laurent Arthaud
Mr. Laurent Arthaud
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Rainer J. Boehm, M.D.
Dr. Rainer J. Boehm, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Cellectis SA?
Die fünf größten Anteilseigner von Cellectis SA sind: Dr. Andre Choulika, Ph.D.
Wie viele Institutionen halten Anteile an Cellectis SA (CLLS)?
Mit Stand vom 2026Q1 halten 77 Institutionen Anteile an Cellectis SA, mit einem Gesamtmarktwert von etwa 12.30M, was 17.00% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -5544701.00 gestiegen.